Investment Summary

EQT Life Sciences Invests In XyloCor Therapeutics

On March 22, 2021, growth capital firm EQT Life Sciences invested in leisure company XyloCor Therapeutics

Investment Highlights
  • This is EQT Life Sciences’ 1st transaction in the Leisure sector.
  • This is EQT Life Sciences’ 7th transaction in the United States.
  • This is EQT Life Sciences’ 1st transaction in Pennsylvania.

Investment Summary

Date 2021-03-22
Target XyloCor Therapeutics
Sector Leisure
Investor(s) EQT Life Sciences
Deal Type Venture

Target

XyloCor Therapeutics

Wayne, Pennsylvania, United States
XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of gene therapy for the significant unmet patient needs in advanced coronary artery disease. XyloCor Therapeutics was founded in 2013 and is based in Wayne, Pennsylvania.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

EQT Life Sciences


Category Growth Capital Firm
Founded 1987
PE ASSETS 2.0B USD
Size Large
Type Sector Focused
DESCRIPTION


DEAL STATS #
Overall 35 of 47
Sector (Leisure) 1 of 1
Type (Venture) 29 of 39
State (Pennsylvania) 1 of 1
Country (United States) 7 of 11
Year (2021) 3 of 12
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-02-25 Simplify

Sunnyvale, California, United States

Simplify is a medical device company focused on cervical spinal disc arthroplasty, using innovative, MRI-compatible materials designed to optimize diagnostic imaging and decrease the need for ionizing radiation. Simplify was founded in 2013 and is based in Sunnyvale, California.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-06-07 Innovative Molecules

Munich, Germany

Innovative Molecules is a drug development company focused on developing next-generation treatments for Herpes simplex-induced diseases. Innovative Molecules is based in Munich, Germany.

Buy -